401 related articles for article (PubMed ID: 15918296)
21. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study.
Werfel T; Breuer K; Ruéff F; Przybilla B; Worm M; Grewe M; Ruzicka T; Brehler R; Wolf H; Schnitker J; Kapp A
Allergy; 2006 Feb; 61(2):202-5. PubMed ID: 16409197
[TBL] [Abstract][Full Text] [Related]
22. Intranasal immunotherapy with Dermatophagoides extract: in vivo and in vitro results of a double-blind placebo-controlled trial.
Fanales-Belasio E; Ciofalo A; Zambetti G; Ansotegui IJ; Scala E; Paganelli R; Filiaci F
Rhinology; 1995 Sep; 33(3):126-31. PubMed ID: 8560161
[TBL] [Abstract][Full Text] [Related]
23. [The changes of serumal eosinophil cationic protein of patients with allergic rhinitis with specific immunotherapy].
Chen J; Zhou N; Huang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Apr; 25(8):347-8. PubMed ID: 21761706
[TBL] [Abstract][Full Text] [Related]
24. Effect of specific immunotherapy versus loratadine on serum adhesion molecules.
Ferreira MB; Santos MC; Pregal AL; Alonso E; Santos AS; Palma-Carlos ML; Palma-Carlos AG
Allerg Immunol (Paris); 2001 Oct; 33(8):319-22. PubMed ID: 11763722
[TBL] [Abstract][Full Text] [Related]
25. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting.
Marogna M; Spadolini I; Massolo A
Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):135-42. PubMed ID: 15916014
[TBL] [Abstract][Full Text] [Related]
26. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy.
Tonnel AB; Scherpereel A; Douay B; Mellin B; Leprince D; Goldstein N; Delecluse P; Andre C
Allergy; 2004 May; 59(5):491-7. PubMed ID: 15080829
[TBL] [Abstract][Full Text] [Related]
27. [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study].
Silny W; Czarnecka-Operacz M
Pol Merkur Lekarski; 2006 Dec; 21(126):558-65. PubMed ID: 17405298
[TBL] [Abstract][Full Text] [Related]
28. [The results of specific immunotherapy for house dust mites in patients with allergic rhinitis].
Sahin E; Taş E; Dağtekin Ergür EN; Cuhali BD; Gürsel AO
Kulak Burun Bogaz Ihtis Derg; 2008; 18(2):79-84. PubMed ID: 18628641
[TBL] [Abstract][Full Text] [Related]
29. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis.
Di Lorenzo G; Drago A; Esposito Pellitteri M; Candore G; Colombo A; Gervasi F; Pacor ML; Purello D'Ambrosio F; Caruso C
Int Arch Allergy Immunol; 2001 Jun; 125(2):164-75. PubMed ID: 11435734
[TBL] [Abstract][Full Text] [Related]
30. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results.
Kim ST; Han DH; Moon IJ; Lee CH; Min YG; Rhee CS
Am J Rhinol Allergy; 2010; 24(4):271-5. PubMed ID: 20819465
[TBL] [Abstract][Full Text] [Related]
31. Mediator release of neuropeptides after nasal provocation in perennial allergic rhinitis patients.
Gawlik R; DuBuske L
Rhinology; 2010 Jun; 48(2):206-10. PubMed ID: 20502762
[TBL] [Abstract][Full Text] [Related]
32. In vitro diagnosis of chronic nasal inflammation.
Kramer MF; Burow G; Pfrogner E; Rasp G
Clin Exp Allergy; 2004 Jul; 34(7):1086-92. PubMed ID: 15248854
[TBL] [Abstract][Full Text] [Related]
33. A multicenter trial of specific local nasal immunotherapy.
Motta G; Passali D; De Vincentiis I; Ottaviani A; Maurizi M; Sartoris A; Pallestrini E; Motta S; Salzano FA
Laryngoscope; 2000 Jan; 110(1):132-9. PubMed ID: 10646729
[TBL] [Abstract][Full Text] [Related]
34. Diminished response to grass pollen allergen challenge in subjects with concurrent house dust mite allergy.
Reinartz SM; van Ree R; Versteeg SA; Zuidmeer L; van Drunen CM; Fokkens WJ
Rhinology; 2009 Jun; 47(2):192-8. PubMed ID: 19593978
[TBL] [Abstract][Full Text] [Related]
35. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.
Tulic MK; Fiset PO; Christodoulopoulos P; Vaillancourt P; Desrosiers M; Lavigne F; Eiden J; Hamid Q
J Allergy Clin Immunol; 2004 Feb; 113(2):235-41. PubMed ID: 14767435
[TBL] [Abstract][Full Text] [Related]
36. Effect of allergen immunotherapy on soluble adhesion molecules.
Pereira-Santos MC; Pregal AL; Spínola-Santos A; Alonso E; Palma-Carlos ML; Palma-Carlos AG
Allerg Immunol (Paris); 2001 Jun; 33(6):225-8. PubMed ID: 11505805
[TBL] [Abstract][Full Text] [Related]
37. Indices of lower airway inflammation in children monosensitized to house dust mite after nasal allergen challenge.
Inal A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB; Erdogan S
Allergy; 2008 Oct; 63(10):1345-51. PubMed ID: 18782114
[TBL] [Abstract][Full Text] [Related]
38. Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children.
Cevit O; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
J Investig Allergol Clin Immunol; 2007; 17(5):286-91. PubMed ID: 17982919
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
[TBL] [Abstract][Full Text] [Related]
40. Nasal eosinophils correlate with FEV1 in patients with perennial allergic rhinitis associated to asthma.
Ciprandi G; Milanese M; Tosca MA; Cirillo I; Vizzaccaro A; Ricca V
Eur Ann Allergy Clin Immunol; 2004 Dec; 36(10):363-5. PubMed ID: 15662963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
